// App-Quantinova.ai

: Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.

Researchers

Presenter

  • Archana Agarwal

Principal Investigators

  • Gregory Russell Pond

  • Catherine Curran

  • Amin Nassar

  • Pier Vitale Nuzzo

  • Vivek Kumar

  • Bradley Alexander McGregor

  • Xiao X. Wei

  • Lauren Christine Harshman

  • Toni K. Choueiri

  • Kerry L. Kilbridge

  • Guru Sonpavde

Medical Centers

  • Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton, MA

  • McMaster University, Hamilton, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved